Ad-hoc announcements

HAEMATO AG Ad-Hoc-News from 07.07.2017:

In today's meeting, the Supervisory Board of HAEMATO AG ("HAEMATO" or the "Company") accepted the wish of Dr. Christian Pahl to not extend his contract as Management Board Member beyond the current term ending 31 July 2017. The Supervisory Board regrets this decision. Dr. Pahl has been a member of the Management Board of HAEMATO since May 2012.

Upon leaving the Company at the end of his term on his own request, Dr. Pahl wishes to devote himself to new tasks.

In today's Supervisory Board meeting, Mr. Uwe Zimdars was appointed Chief Executive Officer and Mr. Daniel Kracht was appointed Chief Financial Officer.

Mr. Uwe Zimdars holds a degree in business management and began his career in the Auditing and Management Consulting division of Arthur Andersen. Later, Mr. Zimdars led a large logistics services provider as managing director for several years. His core experiences are in the fields of strategic and operational planning as well as digitalization.

Mr. Daniel Kracht, after his studies of business management, has held several posi-tions in tax advisory and commercial planning. Since 2011, Mr. Kracht has been part of HAEMATO's leadership team as Head of Group Accounting and Controlling. Since 1 January 2017, Mr. Kracht is a member of the Management Board of HAEMATO PHARM GmbH.

Both have extensive experience in the healthcare industry and the Supervisory Board looks forward to a productive cooperation with Mr. Zimdars and Mr. Kracht.

About HAEMATO:

HAEMATO AG, which was founded in 1993, is a pharmaceutical company. The focus of the operational activities is on the growth markets of patent-free and patent-protected pharmaceuticals. Focal points are therapies of cancer, HIV, and other chronic diseases.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures for the HAEMATO AG share:

Subscribed capital: EUR 21.980.000

Listed class of share: Bearer shares

ISIN: DE000619070

WKN: 619070

Ticker symbol: HAE

 

 

 

Publication of inside information in accordance with Article 17 MAR

05.05.2017 HAEMATO AG: Capital increase from authorized capital with the exclusion of the subscription rights of the existing shareholders decided and successfully implemented.

The Management Board of HAEMATO AG, Schönefeld, (ISIN: DE0006190705) decided today, with the approval of the Supervisory Board, on the basis of the authorized capital of the company to increase the share capital by EUR 1,202,102.00 excluding shareholders' subscription rights. The capital increase has been successfully implemented.

The share capital of the company will increase by EUR 1,201,102.00 from EUR 20,778,898.00 to EUR 21,980,000.00 with the short-term expected entry of the capital increase in the commercial register.

The new shares were placed at a price of EUR 6.20 per share. The shares were subscribed by MPH Mittelstandische Pharma Holding AG.

The company generated gross issue proceeds of around EUR 7.4 million from the capital increase. The proceeds from the capital increase are intended to further strengthen the equity of HAEMATO AG and create the prerequisites for the consistent implementation of the growth strategy of the HAEMATO Group.

In particular, the development of products with attractive margins is to be further expanded.

First Berlin acted as advisor to HAEMATO AG.

 

Communicating person and contact:

Dr. Christian Pahl

CEO

Haemato AG

Lilienthalstraße 5c

12529 Schönefeld, Deutschland

Tel.: 030-6779867600

Fax: 030-677986707

Email: ir@haemato.de

 

Language: englisch

Company:

Haemato AG

Lilienthalstraße 5c

12529 Schönefeld

Deutschland

Telephone: 030-6779867600 

Fax: 030-677986707 

Email: ir@haemato.de

Internet: www.haemato.de

ISIN: DE000619070

WKN: 619070

Stock exchange: Frankfurt am Main (Open Market), Berlin, Düsseldorf, Hamburg, 

Stuttgart

preview-dummy-image

Die HAEMATO AG ist ein börsennotiertes pharmazeutisches Unternehmen mit Fokus auf die Wachstumsmärkte der hochpreisigen Spezial-Pharmazeutika aus den...

preview-dummy-image

Die HAEMATO AG ist ein börsennotiertes pharmazeutisches Unternehmen mit Fo-kus auf die Wachstumsmärkte patentfreier und patentgeschützter Arzneimittel...

preview-dummy-image

IFRS-Ergebnis Q1 2017, Umsatz 67,9 Mio. Euro (Vorjahresperiode: 67,9 Mio. Euro), EBIT 2,8 Mio. Euro (Vorjahresperiode: 3,5 Mio. Euro)...

Order service - Telephone: +49 30 677 98 67 60
Aktuelle News